Robert W Cross

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1301494/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against lethal Nipah virus disease. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2200065119.	7.1	27
2	Reversion of Ebolavirus Disease from a Single Intramuscular Injection of a Pan-Ebolavirus Immunotherapeutic. Pathogens, 2022, 11, 655.	2.8	5
3	Establishment of an African green monkey model for COVID-19 and protection against re-infection. Nature Immunology, 2021, 22, 86-98.	14.5	162
4	Transcriptional Analysis of Lymphoid Tissues from Infected Nonhuman Primates Reveals the Basis for Attenuation and Immunogenicity of an Ebola Virus Encoding a Mutant VP35 Protein. Journal of Virology, 2021, 95, .	3.4	2
5	A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus. Npj Vaccines, 2021, 6, 23.	6.0	45
6	Therapy for Argentine hemorrhagic fever in nonhuman primates with a humanized monoclonal antibody. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	8
7	Combination therapy protects macaques against advanced Marburg virus disease. Nature Communications, 2021, 12, 1891.	12.8	37
8	Use of convalescent serum reduces severity of COVID-19 in nonhuman primates. Cell Reports, 2021, 34, 108837.	6.4	23
9	The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. Science Translational Medicine, 2021, 13, .	12.4	347
10	Broadly neutralizing antibody cocktails targeting Nipah virus and Hendra virus fusion glycoproteins. Nature Structural and Molecular Biology, 2021, 28, 426-434.	8.2	33
11	Ebola vaccine–induced protection in nonhuman primates correlates with antibody specificity and Fc-mediated effects. Science Translational Medicine, 2021, 13, .	12.4	22
12	Recombinant Protein Filovirus Vaccines Protect Cynomolgus Macaques From Ebola, Sudan, and Marburg Viruses. Frontiers in Immunology, 2021, 12, 703986.	4.8	23
13	Development of a SARS-CoV-2 Vaccine Candidate Using Plant-Based Manufacturing and a Tobacco Mosaic Virus-like Nano-Particle. Vaccines, 2021, 9, 1347.	4.4	37
14	An Intranasal Exposure Model of Lethal Nipah Virus Infection in African Green Monkeys. Journal of Infectious Diseases, 2020, 221, S414-S418.	4.0	17
15	Endotheliopathy and Platelet Dysfunction as Hallmarks of Fatal Lassa Fever. Emerging Infectious Diseases, 2020, 26, 2625-2637.	4.3	13
16	Antibodies from Sierra Leonean and Nigerian Lassa fever survivors cross-react with recombinant proteins representing Lassa viruses of divergent lineages. Scientific Reports, 2020, 10, 16030.	3.3	15
17	Potent Henipavirus Neutralization by Antibodies Recognizing Diverse Sites on Hendra and Nipah Virus Receptor Binding Protein. Cell, 2020, 183, 1536-1550.e17.	28.9	28
18	Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment. Nature Communications, 2020, 11, 3736.	12.8	11

ROBERT W CROSS

#	Article	IF	CITATIONS
19	Crimean-Congo hemorrhagic fever virus strains Hoti and Afghanistan cause viremia and mild clinical disease in cynomolgus monkeys. PLoS Neglected Tropical Diseases, 2020, 14, e0008637.	3.0	18
20	Intranasal exposure of African green monkeys to SARS-CoV-2 results in acute phase pneumonia with shedding and lung injury still present in the early convalescence phase. Virology Journal, 2020, 17, 125.	3.4	54
21	Early Transcriptional Changes within Liver, Adrenal Gland, and Lymphoid Tissues Significantly Contribute to Ebola Virus Pathogenesis in Cynomolgus Macaques. Journal of Virology, 2020, 94, .	3.4	8
22	Structure and Characterization of Crimean-Congo Hemorrhagic Fever Virus GP38. Journal of Virology, 2020, 94, .	3.4	28
23	Immune correlates of postexposure vaccine protection against Marburg virus. Scientific Reports, 2020, 10, 3071.	3.3	22
24	Resistance of Cynomolgus Monkeys to Nipah and Hendra Virus Disease Is Associated With Cell-Mediated and Humoral Immunity. Journal of Infectious Diseases, 2020, 221, S436-S447.	4.0	21
25	Rational design of universal immunotherapy for TfR1-tropic arenaviruses. Nature Communications, 2020, 11, 67.	12.8	16
26	Analysis of a Therapeutic Antibody Cocktail Reveals Determinants for Cooperative and Broad Ebolavirus Neutralization. Immunity, 2020, 52, 388-403.e12.	14.3	71
27	A Cross-Reactive Humanized Monoclonal Antibody Targeting Fusion Glycoprotein Function Protects Ferrets Against Lethal Nipah Virus and Hendra Virus Infection. Journal of Infectious Diseases, 2020, 221, S471-S479.	4.0	39
28	Convergent Structures Illuminate Features for Germline Antibody Binding and Pan-Lassa Virus Neutralization. Cell, 2019, 178, 1004-1015.e14.	28.9	39
29	Antibody therapy for Lassa fever. Current Opinion in Virology, 2019, 37, 97-104.	5.4	28
30	Use of reverse genetics to inform Ebola outbreak responses. Lancet Infectious Diseases, The, 2019, 19, 925-927.	9.1	3
31	Antagonism of STAT1 by Nipah virus P gene products modulates disease course but not lethal outcome in the ferret model. Scientific Reports, 2019, 9, 16710.	3.3	19
32	A VP35 Mutant Ebola Virus Lacks Virulence but Can Elicit Protective Immunity to Wild-Type Virus Challenge. Cell Reports, 2019, 28, 3032-3046.e6.	6.4	22
33	Vesicular Stomatitis Virus-Based Vaccine Protects Mice against Crimean-Congo Hemorrhagic Fever. Scientific Reports, 2019, 9, 7755.	3.3	43
34	A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates. Cell Host and Microbe, 2019, 25, 49-58.e5.	11.0	82
35	Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death. Journal of Clinical Investigation, 2019, 130, 539-551.	8.2	40
36	Field validation of recombinant antigen immunoassays for diagnosis of Lassa fever. Scientific Reports, 2018, 8, 5939.	3.3	39

ROBERT W CROSS

#	Article	IF	CITATIONS
37	Post-exposure treatments for Ebola and Marburg virus infections. Nature Reviews Drug Discovery, 2018, 17, 413-434.	46.4	104
38	Efficacy of Human Monoclonal Antibody Monotherapy Against Bundibugyo Virus Infection in Nonhuman Primates. Journal of Infectious Diseases, 2018, 218, S565-S573.	4.0	13
39	Small animal models of filovirus disease: recent advances and future directions. Expert Opinion on Drug Discovery, 2018, 13, 1027-1040.	5.0	19
40	Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates. Journal of Infectious Diseases, 2018, 218, S582-S587.	4.0	28
41	Marburg and Ravn Viruses Fail to Cause Disease in the Domestic Ferret (Mustela putorius furo). Journal of Infectious Diseases, 2018, 218, S448-S452.	4.0	13
42	Comparative Transcriptomics in Ebola Makona-Infected Ferrets, Nonhuman Primates, and Humans. Journal of Infectious Diseases, 2018, 218, S486-S495.	4.0	15
43	Infection with the Makona variant results in a delayed and distinct host immune response compared to previous Ebola virus variants. Scientific Reports, 2017, 7, 9730.	3.3	35
44	Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever. Nature Medicine, 2017, 23, 1146-1149.	30.7	95
45	Transcriptome Analysis of Circulating Immune Cell Subsets Highlight the Role of Monocytes in Zaire Ebola Virus Makona Pathogenesis. Frontiers in Immunology, 2017, 8, 1372.	4.8	49
46	Production of Antigens for ELISA. Methods in Molecular Biology, 2017, 1628, 353-362.	0.9	2
47	ELISA Methods for the Detection of Ebolavirus Infection. Methods in Molecular Biology, 2017, 1628, 363-372.	0.9	3
48	siRNA rescues nonhuman primates from advanced Marburg and Ravn virus disease. Journal of Clinical Investigation, 2017, 127, 4437-4448.	8.2	26
49	An Outbreak of Ebola Virus Disease in the Lassa Fever Zone. Journal of Infectious Diseases, 2016, 214, S110-S121.	4.0	34
50	Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. Nature Communications, 2016, 7, 11544.	12.8	148
51	Nipah Virus C and W Proteins Contribute to Respiratory Disease in Ferrets. Journal of Virology, 2016, 90, 6326-6343.	3.4	41
52	Analytical Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection. Journal of Infectious Diseases, 2016, 214, S210-S217.	4.0	35
53	Treatment of Lassa virus infection in outbred guinea pigs with first-in-classÂhuman monoclonal antibodies. Antiviral Research, 2016, 133, 218-222.	4.1	57
54	Field Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection. Journal of Infectious Diseases, 2016, 214, S203-S209.	4.0	29

ROBERT W CROSS

#	Article	IF	CITATIONS
55	The Domestic Ferret (<i>Mustela putorius furo</i>) as a Lethal Infection Model for 3 Species of <i>Ebolavirus</i> . Journal of Infectious Diseases, 2016, 214, 565-569.	4.0	80
56	Pathogenic Differences between Nipah Virus Bangladesh and Malaysia Strains in Primates: Implications for Antibody Therapy. Scientific Reports, 2016, 6, 30916.	3.3	121
57	Development of Prototype Filovirus Recombinant Antigen Immunoassays. Journal of Infectious Diseases, 2015, 212, S359-S367.	4.0	30
58	Multiple Circulating Infections Can Mimic the Early Stages of Viral Hemorrhagic Fevers and Possible Human Exposure to Filoviruses in Sierra Leone Prior to the 2014 Outbreak. Viral Immunology, 2015, 28, 19-31.	1.3	33
59	Modeling the Disease Course of <i>Zaire ebolavirus</i> Infection in the Outbred Guinea Pig. Journal of Infectious Diseases, 2015, 212, S305-S315.	4.0	43
60	The immunomodulating V and W proteins of Nipah virus determine disease course. Nature Communications, 2015, 6, 7483.	12.8	78
61	Comparison of the Pathogenesis of the Angola and Ravn Strains of Marburg Virus in the Outbred Guinea Pig Model. Journal of Infectious Diseases, 2015, 212, S258-S270.	4.0	38
62	Lassa Fever in Post-Conflict Sierra Leone. PLoS Neglected Tropical Diseases, 2014, 8, e2748.	3.0	172
63	Old World Hantaviruses in Rodents in New Orleans, Louisiana. American Journal of Tropical Medicine and Hygiene, 2014, 90, 897-901.	1.4	10
64	Single injection recombinant vesicular stomatitis virus vaccines protect ferrets against lethal Nipah virus disease. Virology Journal, 2013, 10, 353.	3.4	64
65	Old World Hantavirus Infection in Rattus Species and Risk Management in Urban Neighborhoods of New Orleans, Louisiana. Proceedings of the Vertebrate Pest Conference, 2012, 25, .	0.1	0
66	Dengue virus-pandemic influenza virus co-infection results in enhanced influenza virus replication through inhibition of apoptosis. Retrovirology, 2012, 9, .	2.0	0
67	Genetic Diversity and Histo-Blood Group Antigen Interactions of Rhesus Enteric Caliciviruses. Journal of Virology, 2010, 84, 8617-8625.	3.4	113